Avalo Therapeutics, Inc. is focused on advancing a pipeline of novel IL-1β therapies to address unmet medical needs.
Their lead compound, AVTX-009, shows potential for a best-in-class profile in treating immune-mediated inflammatory diseases like hidradenitis suppurativa (HS).
The company's management team boasts significant experience in pharma and biotech, enhancing their capabilities to bring innovative treatments to market.
Lead Compound AVTX-009
AVTX-009 has 15x higher affinity and a longer half-life than current therapies, potentially leading to higher efficacy and less frequent dosing.
Phase 2 LOTUS Trial
Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in Q2 2026, targeting a market expected to exceed $10 billion by 2035.
Management Team Expertise
Avalo's management team, with over 220 years of combined experience in biotech/pharma, strengthens the company's leadership and strategic direction.
- AVTX-009 targets the inflammatory driver of HS, a chronic and debilitating skin disease, with the potential to address significant unmet medical needs.
- The completion of enrollment for the LOTUS trial signifies a critical milestone for Avalo Therapeutics, paving the way for potential breakthroughs in treating immune-mediated inflammatory diseases.
Avalo Therapeutics' innovative approach to developing novel IL-1β therapies, exemplified by AVTX-009 and the Phase 2 LOTUS trial, positions the company as a key player in addressing unmet medical needs and advancing treatments for immune-mediated inflammatory diseases.